Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging
Antiangiogenic treatment using bevacizumab in brain tumor patients may cause difficulties in the diagnosis of tumor progression (ie, nonenhancing tumor progression). Newly defined criteria for treatment assessment and diagnosis of tumor progression (ie, RANO [Response Assessment in Neuro-Oncology] c...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2013-07-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2013.00051 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561887458721792 |
|---|---|
| author | Norbert Galldiks Marion Rapp Gabriele Stoffels Veronika Dunkl Michael Sabel Karl-Josef Langen |
| author_facet | Norbert Galldiks Marion Rapp Gabriele Stoffels Veronika Dunkl Michael Sabel Karl-Josef Langen |
| author_sort | Norbert Galldiks |
| collection | DOAJ |
| description | Antiangiogenic treatment using bevacizumab in brain tumor patients may cause difficulties in the diagnosis of tumor progression (ie, nonenhancing tumor progression). Newly defined criteria for treatment assessment and diagnosis of tumor progression (ie, RANO [Response Assessment in Neuro-Oncology] criteria) have implemented signal alterations on T 2 /fluid-attenuated inversion recovery (FLAIR) sequences to changes in contrast enhancement. However, T 2 /FLAIR hyperintensity may be influenced by other causes (eg, radiation-induced leukoencephalopathy, peritumoral edema, gliosis). Positron emission tomography using the radiolabeled amino acid O-(2-[ 18 F]fluoroethyl)-L-tyrosine ( 18 F-FET-PET) may help detect the metabolically active tumor extent. We present 18 F-FET-PET imaging findings in a glioblastoma patient during bevacizumab treatment suggesting an earlier diagnosis of tumor progression than magnetic resonance imaging changes, which are based on the RANO criteria. |
| format | Article |
| id | doaj-art-d6077fccfd644dfc8225d1aefa3c2699 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2013-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-d6077fccfd644dfc8225d1aefa3c26992025-01-03T01:22:46ZengSAGE PublishingMolecular Imaging1536-01212013-07-011210.2310/7290.2013.0005110.2310_7290.2013.00051Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance ImagingNorbert GalldiksMarion RappGabriele StoffelsVeronika DunklMichael SabelKarl-Josef LangenAntiangiogenic treatment using bevacizumab in brain tumor patients may cause difficulties in the diagnosis of tumor progression (ie, nonenhancing tumor progression). Newly defined criteria for treatment assessment and diagnosis of tumor progression (ie, RANO [Response Assessment in Neuro-Oncology] criteria) have implemented signal alterations on T 2 /fluid-attenuated inversion recovery (FLAIR) sequences to changes in contrast enhancement. However, T 2 /FLAIR hyperintensity may be influenced by other causes (eg, radiation-induced leukoencephalopathy, peritumoral edema, gliosis). Positron emission tomography using the radiolabeled amino acid O-(2-[ 18 F]fluoroethyl)-L-tyrosine ( 18 F-FET-PET) may help detect the metabolically active tumor extent. We present 18 F-FET-PET imaging findings in a glioblastoma patient during bevacizumab treatment suggesting an earlier diagnosis of tumor progression than magnetic resonance imaging changes, which are based on the RANO criteria.https://doi.org/10.2310/7290.2013.00051 |
| spellingShingle | Norbert Galldiks Marion Rapp Gabriele Stoffels Veronika Dunkl Michael Sabel Karl-Josef Langen Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging Molecular Imaging |
| title | Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging |
| title_full | Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging |
| title_fullStr | Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging |
| title_full_unstemmed | Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging |
| title_short | Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging |
| title_sort | earlier diagnosis of progressive disease during bevacizumab treatment using o 2 f fluorethyl l tyrosine positron emission tomography in comparison with magnetic resonance imaging |
| url | https://doi.org/10.2310/7290.2013.00051 |
| work_keys_str_mv | AT norbertgalldiks earlierdiagnosisofprogressivediseaseduringbevacizumabtreatmentusingo2ffluorethylltyrosinepositronemissiontomographyincomparisonwithmagneticresonanceimaging AT marionrapp earlierdiagnosisofprogressivediseaseduringbevacizumabtreatmentusingo2ffluorethylltyrosinepositronemissiontomographyincomparisonwithmagneticresonanceimaging AT gabrielestoffels earlierdiagnosisofprogressivediseaseduringbevacizumabtreatmentusingo2ffluorethylltyrosinepositronemissiontomographyincomparisonwithmagneticresonanceimaging AT veronikadunkl earlierdiagnosisofprogressivediseaseduringbevacizumabtreatmentusingo2ffluorethylltyrosinepositronemissiontomographyincomparisonwithmagneticresonanceimaging AT michaelsabel earlierdiagnosisofprogressivediseaseduringbevacizumabtreatmentusingo2ffluorethylltyrosinepositronemissiontomographyincomparisonwithmagneticresonanceimaging AT karljoseflangen earlierdiagnosisofprogressivediseaseduringbevacizumabtreatmentusingo2ffluorethylltyrosinepositronemissiontomographyincomparisonwithmagneticresonanceimaging |